Teva announced the launch of Buprenorphine Transdermal System, the generic of Purdue‘s Butrans (buprenorphine) Transdermal System.

Buprenorphine Transdermal System, a CIII controlled substance, is indicated for the management of pain that is severe enough to require daily, around-the-clock, long-term opioid treatment and inadequately managed by other treatment. Extended-release opioid formulations must be reserved only for use in patients who are ineffectively managed with non-opioid analgesics or immediate-release opioids

Related Articles

Buprenorphine is a partial agonist at the mu-opioid receptor and ORL-1 receptors, an agonist at delta-opioid receptors, and an antagonist at kappa-opioid receptors. The direct contributions of these actions to analgesia are unknown but it has a broad systemic effect and may induce respiratory depression, mioisis, reduced motility, vasodilation, hypotension and adrenal suppression, among others.

Teva’s Buprenorphine Transdermal System is available in 4 individually-packaged systems per carton in the following strengths: 5mcg/hr, 10mcg/hr, 15mcg/hr, 20mcg/hr. 

For more information call (888) 838-2872 visit